Good morning Team Canary,

Ms. Sarah was diagnosed Hormone positive Breast cancer (low risk) at a young age of 33years in 2022. She received incomplete treatment from her country and was not made aware of the infertility issues that goes with chemo rendering her infertile.

Since she has a positive family with her sister, we have now found out the mutation responsible for Breast cancer -PTEN. Besides that, she has an actionable mutation in PI3CKA which is a major mutation that can cause endocrine resistance in Breast cancer leading to development of early recurrence or metastasis even though she is low risk Hormone positive. She also has a high tumor mutation burden for which we can initiate Immunotherapy. Once again, to all my dearest Canary members, I feel proud to be associated with this Institute and thank you for helping me treat this kind lady.

Thank you.

Hi Team Canary,

Mr. Selvam is diagnosed with Carcinoma Hepatic flexure Colon ( right) and intriguingly he has bone metastasis which is uncommon in Colon cancers. He also has a positive family history in his father with Colon cancer.

Now he has BRAF V600E mutation and PTEN , the latter has syndrome association with COWDEN Syndrome.

I thank my Canary team for helping me with the report.

Hi Operations Team,

Wishing You a Very Happy New Year, may all stay blessed with a healthy life.

This particular patient Mr. Panchap 75 year old has an intriguing history. He has Metastatic Castrate sensitive Prostate cancer with Extensive spread to Lung , Bones and Nodes . The interesting part here is his PSA is 1.6ng/ml. Usually with this amount of disease, the PSA ought to be off charts .

So, I was sceptical whether chemotherapy would be of any use to him, and since he also has a positive family history amongst his relative, we pursued the NGS testing through Canary Oncoceutics.

He has a BRCA2 mutation which has familial predisposition to Breast, ovary, Prostate, gall bladder, stomach, melanoma, male breast cancer.

I sincerely thank Dr. Harry and his wonderful team for this report. This report will provide a new perspective for myself , the caregiver and the patient in terms of disease control and QOL ( Quality of Life )

Much appreciated.

Good evening to All.

Thank You very much for providing Mr. Anbaz’s (name changed) report. He was diagnosed in 2019 with Glioblastoma Multiforme, he completed treatment protocol and was off chemo for 1 year when he developed recurrence.

Now we did NGS from our Canary Oncoceuticals and believe me, I am overjoyed to see this report. He has IDH R132H mutation where in Arginine replaces Histidine at position 132 which confers a very good Progression free survival and Overall survival (The OS of GBM is only 12 ton18 months)

He also has a CCND2 Mutation for which we can try Abemaciclib at the time of recurrence.

Also his TMB is high for which I had initially planned NIVOLUMAB ( Immunotherapy) provides i get this report and I have!

Much appreciated Dear Harry Sir and Team

Hi Dr. Harry,

I read Mrs. Lakashmi’s (name changed) report. It's profoundly impressive wherein her study on the breast biopsy has revealed - MLH1, HER2 , MSH3 and a high TMB. Practical enough to follow Immunotherapy as maintenance after she completes her chemotherapy sessions. Regarding the ovarian biopsy, mutation in TP53, is likely a somatic. What is impressive, that she comes under the umbrella of Lynch syndrome.

I am really impressed with the reporting and efficacy it has demanded.

He also has a CCND2 Mutation for which we can try Abemaciclib at the time of recurrence.

Thank you.

Hi Dr Harry,

Thank you very much, here is my feedback on two of my patients who has undergone NGS testing at Canary. (1). 58 year male with lung adenocarcinoma. Initial NGS testing went to a local Indian company with negative results. We sent the same sample to Canary and interestingly a RET-CCDC6 fusion with actionable therapies was detected. The patient was given the recommended targeted therapy and is responding very well. Thank you for such a valuable clinical report.

(2). 52 year female with breast cancer experienced a cardiac event under chemo. The sample was sent for NGS at Canary and a MAP2K2 mutation was detected. I wish I knew she had a MAP2K2 mutation before I had started chemo. As we know MAP2K2 mutations are associated with chemo-induced cardiac events.

Thank you.